Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19983419 | 0.84 | — | — | |
| SCHEMBL22878448 | 0.82 | TSHR (0.46) | TSHR | |
| SCHEMBL18938453 | 0.79 | CYP3A4 (0.45) | TSHR | |
| SCHEMBL23220574 | 0.78 | — | — | |
| SCHEMBL19231803 | 0.76 | CYP2D6 (0.45) | TSHR | |
| SCHEMBL17795542 | 0.76 | — | — | |
| SCHEMBL23987747 | 0.74 | TSHR (0.52) | TSHR | |
| SCHEMBL24784078 | 0.72 | HRH3 (0.38) | HRH3TSHR | |
| SCHEMBL993857 | 0.72 | TSHR (0.36) | HRH3TSHR | |
| SCHEMBL19098325 | 0.72 | HRH3 (0.34) | HRH3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023125627-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LYNK PHARMACEUTICALS CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| EP-3867238-B1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4180422-A1 | SULFONYLBENZAMIDE DERIVATIVE AND CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
| EP-3656769-B1 | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022266015-A1 | FUSED HETEROARYL COMPOUNDS USEFUL AS ANTICANCER AGENTS | KUMQUAT BIOSCIENCES INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-4008719-A2 | PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2022-06-08 | — | — | EP | disclosed |
| EP-3988551-A1 | CDK KINASE INHIBITOR | Beijing Benicall Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| WO-2021058027-A1 | PYRROLO HETEROARYL DERIVATIVE OR CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2020259724-A2 | PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 上海医药集团股份有限公司 | 2020-12-30 | — | — | WO | disclosed |
| WO-2020253458-A1 | CDK KINASE INHIBITOR | 北京睿熙生物科技有限公司 | 2020-12-24 | — | — | WO | disclosed |
| WO-2020151636-A1 | PDE9 INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2020-07-30 | — | — | WO | disclosed |
| WO-2020143626-A1 | PDE9 INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2020-07-16 | — | — | WO | disclosed |
| EP-3656769-A1 | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019062733-A1 | PDE9 INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-04-04 | — | — | WO | disclosed |
| WO-2017133701-A1 | CERTAIN PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2017-08-10 | — | — | WO | disclosed |
| EP-2760862-B1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2015-10-21 | — | — | EP | disclosed |
| WO-2015101293-A1 | KINASE INHIBITOR AND USE THEREOF | 山东轩竹医药科技有限公司 | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | SMN1; SMN2, UTRN, DDX21 | HRH3 3994/4885TSHR 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.